Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

HIKMA PHARMACEUTICALS (HIK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Drugmaker Hikma's FY profit, revenue meet expectations; shares rise

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2018 | 01:36pm CEST

(Reuters) - Hikma Pharmaceuticals Plc (>> Hikma Pharmaceuticals) reported full-year profit and revenue largely in line with expectations, aided by strong performance in the second half of the year.

(Reuters) - Hikma Pharmaceuticals Plc reported full-year profit and revenue largely in line with expectations, aided by strong performance in the second half of the year.

The company has struggled due to persistent price pressures in the U.S. market and was forced to cut revenue guidance for its generics business thrice in 2017.

Hikma's problems were further compounded by a delay in the launch of its generic version of GlaxoSmithKline blockbuster lung drug Advair. The U.S. Food and Drug Administration on Monday asked Hikma to conduct a further clinical study evaluating the drug.

Hikma posted 2017 generics revenue of $615 million, surpassing its expectation of about $600 million.

The company, which named former Teva Pharmaceutical generics head Sigurdur Olafsson as its CEO in a bid to improve the business, forecast revenue from generics in 2018 to be in the range of $550 million to $600 million.

"We see these results as reassuring in the context of poor market sentiment and multiple headwinds to the business and would expect a positive reaction," Morgan Stanley analysts wrote in a note.

Hikma shares rose as much as 10.7 percent in early trading.

The Jordan-based drugmaker said earnings before interest, tax, depreciation and amortisation (EBITDA) fell 5 percent to $468 million for the year ended Dec. 31, but was largely in line with analysts' estimate of $469.9 million, according to Thomson Reuters I/B/E/S.

Revenue fell marginally to $1.94 billion, also keeping with estimates.

(Reporting By Justin George Varghese in Bengaluru; Editing by Saumyadeb Chakrabarty and Sunil Nair)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 3.07% 1531.4 Delayed Quote.15.80%
HIKMA PHARMACEUTICALS -1.01% 1854.5 Delayed Quote.63.54%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2.16% 8848 Delayed Quote.36.04%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on HIKMA PHARMACEUTICALS
09/18HIKMA PHARMACEUTICALS : rsquo; Egypt investments near $300m – MD
AQ
09/18HIKMA PHARMACEUTICALS : rsquo; Egypt investment near $300m – MD
AQ
09/14HIKMA PHARMACEUTICALS : Remains Constituent of FTSE4Good Index Series
AQ
09/10Acorda Shares Tumble After Court Ruling
DJ
08/23HIKMA PHARMACEUTICALS : Ex-dividend day for interim dividend
FA
08/21HIKMA PHARMACEUTICALS : 14.5% Potential Upside Indicated by Citigroup
AQ
08/16HIKMA PHARMACEUTICALS : Appoints Kristy Ronco Executive Vice President, Sales an..
BU
08/16HIKMA PHARMACEUTICALS : shares rise amid injectables shortage
AQ
08/15HIKMA PHARMACEUTICALS PLC : to Host Earnings Call
AC
08/15HIKMA PHARMACEUTICALS : sees higher full-year revenue, shares climb
RE
More news
News from SeekingAlpha
08/15Hikma Pharmaceuticals plc. (HKMPF) CEO Siggi Olafsson on Q2 2018 Results - Ea.. 
08/15Hikma Pharmaceuticals plc. 2018 Q2 - Results - Earnings Call Slides 
08/15Hikma Pharmaceuticals reports 1H results 
07/26Longleaf Partners Shareholder Letter Q2 2018 
04/15Longleaf Partners Shareholder Letter Q1 2018 
Financials ($)
Sales 2018 1 986 M
EBIT 2018 359 M
Net income 2018 223 M
Debt 2018 440 M
Yield 2018 1,42%
P/E ratio 2018 26,67
P/E ratio 2019 25,16
EV / Sales 2018 3,21x
EV / Sales 2019 3,06x
Capitalization 5 944 M
Chart HIKMA PHARMACEUTICALS
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 20,2 $
Spread / Average Target -19%
EPS Revisions
Managers
NameTitle
Sigurdur Oli Olafsson Chief Executive Officer & Director
Said Samih Taleb Darwazah Executive Chairman
Khalid Walid Hosni Nabilsi Chief Financial Officer
Surendera Tyagi Chief Scientific Officer, Global Head-R&D
Bryan Hotston Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
HIKMA PHARMACEUTICALS63.54%5 944
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092